Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02618915 · ClinicalTrials.gov registry record · Phase 1
Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B
A Phase 1 study, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02618915 is a Phase 1 study that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 6 participants.
The verdict
NCT02618915, a Phase 1 study, was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
A Phase 1/2, open-label, dose-finding safety study of single ascending doses of DTX101 in adult males with moderate/severe to severe hemophilia B.
Interventions
- GENETIC DTX101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-12-16 |
| Est. Completion | 2017-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02618915
The ClinicalTrials.gov registry entry for NCT02618915 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DTX101 is the first listed.
NCT02618915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02618915 about?
NCT02618915 is a clinical study titled "Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B". A Phase 1/2, open-label, dose-finding safety study of single ascending doses of DTX101 in adult males with moderate/severe to severe hemophilia B.
What is the current status of trial NCT02618915?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2015-12-16. Estimated completion is 2017-10-18.
What interventions are being tested in trial NCT02618915?
The interventions under investigation include: DTX101 (GENETIC).
Who is sponsoring clinical trial NCT02618915?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.